JP2018513107A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513107A5 JP2018513107A5 JP2017542390A JP2017542390A JP2018513107A5 JP 2018513107 A5 JP2018513107 A5 JP 2018513107A5 JP 2017542390 A JP2017542390 A JP 2017542390A JP 2017542390 A JP2017542390 A JP 2017542390A JP 2018513107 A5 JP2018513107 A5 JP 2018513107A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- pharmaceutical composition
- disorder
- disease
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 239000004480 active ingredient Substances 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 10
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 claims 6
- 208000027601 Inner ear disease Diseases 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 6
- 208000003251 Pruritus Diseases 0.000 claims 6
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 206010011224 Cough Diseases 0.000 claims 3
- 206010021143 Hypoxia Diseases 0.000 claims 3
- 206010021639 Incontinence Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 206010037660 Pyrexia Diseases 0.000 claims 3
- 208000026723 Urinary tract disease Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 230000017531 blood circulation Effects 0.000 claims 3
- 230000001079 digestive effect Effects 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 3
- 230000007954 hypoxia Effects 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 230000028016 temperature homeostasis Effects 0.000 claims 3
- 208000014001 urinary system disease Diseases 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 0 *C(C1)=CC=C1C(C(N([C@@](C1)C(NCC(CC(c2cnc(C(F)(F)F)nc2)N=C2)=C2F)=O)C2(CC2)[C@@]1F)=N)=* Chemical compound *C(C1)=CC=C1C(C(N([C@@](C1)C(NCC(CC(c2cnc(C(F)(F)F)nc2)N=C2)=C2F)=O)C2(CC2)[C@@]1F)=N)=* 0.000 description 3
- KNUQIWPBVMPOGX-WILYLXEWSA-N C[C@@H]([C@@H](C[C@H]1C(NCc2cc(-c3cnc(C(F)(F)F)nc3)ncc2OC(F)(F)F)=O)F)N1S(c(cc1)ccc1F)(=O)=O Chemical compound C[C@@H]([C@@H](C[C@H]1C(NCc2cc(-c3cnc(C(F)(F)F)nc3)ncc2OC(F)(F)F)=O)F)N1S(c(cc1)ccc1F)(=O)=O KNUQIWPBVMPOGX-WILYLXEWSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2015/073102 | 2015-02-15 | ||
| CN2015073102 | 2015-02-15 | ||
| CNPCT/CN2015/076318 | 2015-04-10 | ||
| CN2015076318 | 2015-04-10 | ||
| CNPCT/CN2016/071061 | 2016-01-15 | ||
| CN2016071061 | 2016-01-15 | ||
| PCT/EP2016/052950 WO2016128529A1 (en) | 2015-02-15 | 2016-02-12 | 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513107A JP2018513107A (ja) | 2018-05-24 |
| JP2018513107A5 true JP2018513107A5 (cg-RX-API-DMAC10.html) | 2019-03-22 |
| JP6700291B2 JP6700291B2 (ja) | 2020-05-27 |
Family
ID=55349845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542390A Active JP6700291B2 (ja) | 2015-02-15 | 2016-02-12 | １−（ｈｅｔ）アリールスルホニル−（ピロリジン又はピペリジン）−２−カルボキサミド誘導体、及びｔｒｐａ１拮抗薬としてのそれらの使用 |
Country Status (20)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104364239B (zh) | 2012-06-13 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 二氮杂螺环烷烃和氮杂螺环烷烃 |
| CA2878442A1 (en) | 2012-09-25 | 2014-04-03 | F. Hoffmann-La Roche Ag | Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| PE20160845A1 (es) | 2013-11-26 | 2016-09-10 | Hoffmann La Roche | Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo |
| HUE046820T2 (hu) | 2014-03-26 | 2020-03-30 | Hoffmann La Roche | Biciklusos vegyületek autotaxin (ATX) és lizofoszfatidsav (LPA) termelésgátlókként |
| EA032357B1 (ru) | 2014-03-26 | 2019-05-31 | Ф. Хоффманн-Ля Рош Аг | Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) |
| TWI676626B (zh) * | 2014-04-23 | 2019-11-11 | 美商美國禮來大藥廠 | 抑制瞬時受體電位ａ１離子通道 |
| SMT202000540T1 (it) | 2014-10-06 | 2020-11-10 | Vertex Pharma | Modulatori di regolatore di conduttanza transmembrana di fibrosi cistica |
| KR102594441B1 (ko) | 2015-03-06 | 2023-10-25 | 파마케아, 인크. | 플루오르화된 리실 옥시다아제-유사 2 억제제 및 이의 용도 |
| WO2016144702A1 (en) | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| US20180186755A1 (en) * | 2015-07-01 | 2018-07-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| MX377277B (es) | 2015-09-04 | 2025-03-07 | Hoffmann La Roche | Derivados de fenoximetilo. |
| MA42923A (fr) | 2015-09-24 | 2021-04-28 | Hoffmann La Roche | Composés bicycliques comme inhibiteurs mixtes de atx/ca |
| BR112018006034A2 (pt) | 2015-09-24 | 2018-10-09 | Hoffmann La Roche | compostos bicíclicos como inibidores de atx |
| RU2725138C2 (ru) | 2015-09-24 | 2020-06-30 | Ф. Хоффманн-Ля Рош Аг | Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca) |
| WO2017050732A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
| EA037264B1 (ru) * | 2016-02-05 | 2021-03-01 | Эа Фарма Ко., Лтд. | Гетероциклическое сульфонамидное производное и содержащее его лекарственное средство |
| WO2018015411A1 (en) | 2016-07-20 | 2018-01-25 | F. Hoffmann-La Roche Ag | Sulfonylcycloalkyl carboxamide compounds as trpa1 modulators |
| WO2018015410A1 (en) * | 2016-07-20 | 2018-01-25 | F. Hoffmann-La Roche Ag | Bicyclic proline compounds |
| JP7071959B2 (ja) * | 2016-08-12 | 2022-05-19 | エフ．ホフマン－ラ ロシュ アーゲー | スルホニルピリジルｔｒｐ阻害剤 |
| WO2018048943A1 (en) | 2016-09-07 | 2018-03-15 | Pharmakea, Inc. | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
| BR112019004513A2 (pt) | 2016-09-07 | 2019-06-18 | Pharmakea Inc | usos de um inibidor de lisil oxidase-like 2 |
| UY37513A (es) | 2016-12-09 | 2018-07-31 | Vertex Pharma | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador |
| WO2018109155A1 (en) | 2016-12-16 | 2018-06-21 | Galderma Research & Development | Trpa1 antagonists for use in the treatment of atopic dermatitis |
| WO2018130437A1 (de) | 2017-01-10 | 2018-07-19 | Bayer Aktiengesellschaft | Heterocyclen-derivate als schädlingsbekämpfungsmittel |
| KR20190129924A (ko) | 2017-03-16 | 2019-11-20 | 에프. 호프만-라 로슈 아게 | 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 유용한 헤테로환형 화합물 |
| CN110382484B (zh) | 2017-03-16 | 2022-12-06 | 豪夫迈·罗氏有限公司 | 新的作为atx抑制剂的二环化合物 |
| US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| BR112020000941A2 (pt) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| AU2018309043B2 (en) | 2017-08-02 | 2022-03-31 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
| CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| US11465985B2 (en) * | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| TW202000201A (zh) | 2018-02-20 | 2020-01-01 | 瑞士商赫孚孟拉羅股份公司 | 製備1-芳基磺醯基-吡咯啶-2-甲醯胺瞬時受體電位通道拮抗劑化合物及其結晶型式之方法 |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| CN112739689B (zh) | 2018-12-07 | 2022-06-03 | 优迈特株式会社 | 含氟嘧啶化合物及其制造方法 |
| CN110156834A (zh) * | 2019-06-05 | 2019-08-23 | 镇江市高等专科学校 | 一种黄色荧光铜(i)配合物及其制备方法和应用 |
| CN119504704A (zh) | 2020-05-19 | 2025-02-25 | 优迈特株式会社 | 含氟嘧啶化合物和含氟嘧啶酮化合物 |
| FR3114235A1 (fr) | 2020-09-18 | 2022-03-25 | Université Grenoble Alpes | Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer |
| CA3198930A1 (en) * | 2020-11-19 | 2022-05-27 | Acousia Therapeutics Gmbh | Non-aqueous gel composition |
| IT202100015098A1 (it) | 2021-06-09 | 2022-12-09 | Flonext S R L | Composto antagonista del canale trpa1 per uso in patologie degenerative della retina |
| US20250064846A1 (en) * | 2022-01-07 | 2025-02-27 | The Johns Hopkins University | Treatment and prevention of trigeminal neuralgia |
| AR131541A1 (es) | 2023-01-07 | 2025-04-09 | Syngenta Crop Protection Ag | Compuestos de carboxamida novedosos |
| WO2025109114A1 (en) | 2023-11-24 | 2025-05-30 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
| WO2025149637A1 (en) | 2024-01-12 | 2025-07-17 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2025149629A1 (en) | 2024-01-12 | 2025-07-17 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2025155669A1 (en) * | 2024-01-17 | 2025-07-24 | The Jackson Laboratory | Trpc3 inhibitors and uses thereof |
| WO2026008750A1 (en) | 2024-07-05 | 2026-01-08 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8614201B2 (en) * | 2009-06-05 | 2013-12-24 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of TRPA1 |
| EP2520566A1 (en) * | 2011-05-06 | 2012-11-07 | Orion Corporation | New Pharmaceutical Compounds |
| JP6182072B2 (ja) * | 2012-01-17 | 2017-08-16 | Ｅａファーマ株式会社 | 複素環アミド誘導体及びそれを含有する医薬 |
| WO2014098098A1 (ja) | 2012-12-18 | 2014-06-26 | 味の素株式会社 | 複素環アミド誘導体及びそれを含有する医薬 |
| WO2014113671A1 (en) * | 2013-01-18 | 2014-07-24 | Cubist Pharmaceuticals, Inc. | Inhibiting the transient receptor potential a1 ion channel |
| US9394308B2 (en) * | 2013-01-18 | 2016-07-19 | Merck Sharp & Dohme Corp. | Inhibiting the transient receptor potential A1 ion channel |
| JP2016532673A (ja) | 2013-10-11 | 2016-10-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｔｒｐａ１調節因子として有用な置換複素環式スルホンアミド化合物 |
| KR20160135183A (ko) | 2014-01-28 | 2016-11-25 | 이에이 파마 가부시키가이샤 | 복소환 술폰아미드 유도체 및 그것을 함유하는 의약 |
-
2016
- 2016-02-12 EA EA201791836A patent/EA033497B1/ru not_active IP Right Cessation
- 2016-02-12 CA CA2975196A patent/CA2975196A1/en not_active Abandoned
- 2016-02-12 CR CR20170367A patent/CR20170367A/es unknown
- 2016-02-12 EP EP16703990.8A patent/EP3256463B1/en active Active
- 2016-02-12 WO PCT/EP2016/052950 patent/WO2016128529A1/en not_active Ceased
- 2016-02-12 US US15/042,310 patent/US10179782B2/en active Active
- 2016-02-12 JP JP2017542390A patent/JP6700291B2/ja active Active
- 2016-02-12 BR BR112017017052-3A patent/BR112017017052A2/pt not_active IP Right Cessation
- 2016-02-12 PE PE2017001378A patent/PE20180177A1/es unknown
- 2016-02-12 AU AU2016217851A patent/AU2016217851A1/en not_active Abandoned
- 2016-02-12 CN CN201680009724.XA patent/CN107922392B/zh active Active
- 2016-02-12 MX MX2017010300A patent/MX2017010300A/es unknown
- 2016-02-12 SG SG11201706451TA patent/SG11201706451TA/en unknown
- 2016-02-12 KR KR1020177025946A patent/KR20170118166A/ko not_active Withdrawn
- 2016-02-12 PT PT167039908T patent/PT3256463T/pt unknown
- 2016-02-15 TW TW105104384A patent/TW201639829A/zh unknown
-
2017
- 2017-07-13 IL IL253478A patent/IL253478A0/en unknown
- 2017-07-28 CO CONC2017/0007679A patent/CO2017007679A2/es unknown
- 2017-08-03 CL CL2017001987A patent/CL2017001987A1/es unknown
- 2017-08-15 PH PH12017501478A patent/PH12017501478A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018513107A5 (cg-RX-API-DMAC10.html) | ||
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| JP2020073529A5 (cg-RX-API-DMAC10.html) | ||
| JP2018048154A5 (cg-RX-API-DMAC10.html) | ||
| JP2018513188A5 (cg-RX-API-DMAC10.html) | ||
| JP2014502641A5 (cg-RX-API-DMAC10.html) | ||
| TW201615219A (zh) | 呼吸系統疾病用藥臨床新應用 | |
| JP2015529234A5 (cg-RX-API-DMAC10.html) | ||
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| JP2009510044A5 (cg-RX-API-DMAC10.html) | ||
| MX2017003102A (es) | Formulacion para inhalacion liquida que comprende rpl554. | |
| EA201891931A1 (ru) | Новые ингибиторы фосфатидилинозитол-3-киназы гамма | |
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| JP2020513032A5 (cg-RX-API-DMAC10.html) | ||
| JP2016027060A5 (cg-RX-API-DMAC10.html) | ||
| RU2014141893A (ru) | Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких | |
| JP2017510607A5 (cg-RX-API-DMAC10.html) | ||
| JP2018537507A5 (cg-RX-API-DMAC10.html) | ||
| JP2017522300A5 (cg-RX-API-DMAC10.html) | ||
| HRP20210294T1 (hr) | Postupci liječenja akutnog bubrežnog oštećenja | |
| JP2017105859A5 (cg-RX-API-DMAC10.html) | ||
| JP2017105861A5 (cg-RX-API-DMAC10.html) | ||
| JP2015522603A5 (cg-RX-API-DMAC10.html) | ||
| HRP20191019T1 (hr) | Kombinacijska terapija konjugatom protutijela i lijeka anti-her2 i inhibitorom bcl-2 | |
| CR20210043A (es) | Forma de dosificación farmacèutica administrable por vía oral con liberación modificada |